Aug 04, 2022
Q2 2022 total revenue of $256.5 million , up 386% from $52.8 million for Q2 2021 HEPLISAV-B ®  vaccine net product revenue of $32.7 million, up 139% from $13.7 million for Q2 2021 CpG 1018 ® adjuvant net product revenue of $222.6 million , up 471% from $39.0 million for Q2 2021 On track for second
May 05, 2022
First quarter 2022 total revenue of $114.0 million , up 37% from $83.3 million for Q1 2021 HEPLISAV-B ® vaccine net product revenue of $20.8 million , up 151% from $8.3 million for Q1 2021 CpG 1018® adjuvant net product revenue of $91.5 million , up 23% from $74.6 million for Q1 2021 Guidance